Inventiva Unveils New Biomarker Analysis for MASH Treatment

In a new publication in Clinical Gastroenterology and Hepatology, biopharmaceutical company Inventiva reveals promising findings from its analysis on new biomarker signatures. These signatures aim to accurately predict histological responses in patients with metabolic dysfunction-associated steatohepatitis (MASH) treated with lanifibranor. The biomarker signatures showed promising predictive accuracy, surpassing existing diagnostic scores such as FIB4 and ELF, with AUROC values above 0.80.

This non-invasive method allows for better identification of patient responses, crucial for personalized treatment. The analysis involved 71 biomarkers collected during the NATIVE Phase 2b trial, focusing on MASH resolution and fibrosis improvement.

Inventiva aims to further validate these biomarkers in its ongoing Phase 3 trials, potentially transforming management strategies for chronic liver diseases.